跳至主要内容
临床试验/NCT03972982
NCT03972982Unknown4 期

Induction of Long-term Glycemic Remission Via Structured Simplified Short-term Intensive Insulin Therapy in Patients With Newly Diagnosed Type 2 Diabetes: a Multiple Centered, Randomised Controlled Trial.

Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2019年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
330
试验地点
1
主要终点
remission rate

研究概览

简要总结

Short-term intensive insulin therapy is shown to induced glycemic remission, but traditionally patients were hospitalized for 2-4 weeks in order to receive the therapy, the long inpatient period precluded the wide application of the thrapy. This study aims to invesitgate whether simplified regimen is non-inferior to traditional regimen in achieving long-term glycemic remisson.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • newly diagnosed type 2 diabetes with no prior hypoglycemic agents application, or on hyperglycemic monotherapy for less than 1 week;
  • GHbA1c ≥ 9%
  • Body mass index between 20-35kg/m2
  • Capable to use wearable devices and mobile Apps;
  • willling to follow the study protocol and data collection.

排除标准

  • Type 1 diabetes or specific types of diabetes;
  • Allergic or intolercance to medicine used in the study;
  • Acute diabetic complications (diabetic ketoacidosis, hyperosmotic hyperglycemia coma or lactic acidosis);
  • Severe diabetic microvascular complications (proliferative retinopathy, clinical proteinuria,uncontrolled diabetic neuropathy and obvious diabetic autonomic neuropathy;
  • Glomerular filtration rate less than 50 ml/min
  • ALT >2.5 times of the upper limit of normal (ULN), or bilirubin > 1.5 times of ULN;
  • Significant Macrovascular disease:acute cerebrovascular accident, acute coronary syndrome or peripheral artery disease that required vascular intervention or amputation 12 months before enrollment;
  • Poor blood pressure control (systolic blood pressure≥180mmHg and/or sitting diastolic blood pressure ≥110mmHg) and unable to control under 160/110mmhg within 1 week;
  • Hemoglubin level < 100g/L or required regular blood transfusion;
  • Chronic cardiac dysfunction with NYHA grade III or above;
  • Use of medicines that affect blood glucose for a cumulative time of more than 1 week within the prior 12 weeks, such as oral/venous glucocorticoid, growth hormone, estrogen/ progesterone, high-dose diuretics, antipsychotic drugs. However, low-dose diuretics for antihypertensive purposes (HCTZ < 25mg/d, indapamide < 1.5mg/d) and physiologic replacement of thyroid hormone are allowed;
  • Serious systemic disease or malignant tumor, chronic diarrhea, etc;
  • Uncontrolled abnormalty in endocrine glands (Cushing's syndrome, hyperthyroidism, etc.);
  • Any factors that may affect the participation of the subject in the study or the evaluation of the results;
  • Pregnancy or planned pregnancy, lactation subjects.

研究组 & 干预措施

Simplified regimen group

Experimental

Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week,Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.

干预措施: Simplified intensive insulin therapy regimen (Drug)

Routine group

Active Comparator

Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.

干预措施: Traditional Short-term Intensive insulin therapy (Drug)

结局指标

主要结局

remission rate

时间窗: 24 weeks after withdrawal of the medical intervention

Remission is defined as fasting plasma glucose less than 7mmol/L and GHbA1c less than 7% without any hypoglycemic agents

次要结局

未报告次要终点

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yanbing Li

Professor

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验